Preprint · OA
via OpenAlex
Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Tracy A. Cole, Hien Tran Zhao, Timothy J. Collier, Ivette M. Sandoval, Caryl E. Sortwell, Kathy Steece‐Collier, Brian F. Daley, Alix Booms, Jack W. Lipton, Mackenzie Welch, Melissa Berman, Luke Jandreski, Danielle L. Graham, Andreas Weihofen, Stephanie L. Celano
bioRxiv (Cold Spring Harbor Laboratory) · 2019 · ▲ 10 citations
Abstract
Abstract Parkinson’s disease (PD) is a prevalent neurodegenerative disease with no approved disease-modifying therapies. Multiplications, mutations, and single nucleotide polymorphisms in the SNCA gene, encoding alpha-synuclein protein (aSyn), either cause or increase risk for PD. Intracellular accumulations of aSyn are pathological hallmarks of PD. Taken together, reduction of aSyn production may provide a disease-modifying therapy for PD. We show that antisense oligonucleotides (ASOs) reduce production of aSyn in rodent pre-formed fibril (PFF) models of PD. Reduced aSyn production leads to prevention and removal of established aSyn pathology and prevents dopaminergic cell dysfunction. In addition, we address the translational potential of the approach through characterization of human SNCA targeting ASOs that efficiently suppress the human SNCA transcript in vivo. We demonstrate broad activity and distribution of the human SNCA ASOs throughout the non-human primate brain and a corresponding decrease in aSyn cerebral spinal fluid (CSF) levels. Taken together, these data suggest that by inhibiting production of aSyn it may be possible to reverse established pathology and thus supports the development of SNCA ASOs as a potentially disease modifying therapy for PD and related synucleinopathies. Summary Antisense oligonucleotides designed against SNCA , which are progressing to the clinic, have the potential to be a disease modifying therapeutic for Parkinson’s disease patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1101/830554
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Cole, T.A., Zhao, H.T., Collier, T.J., Sandoval, I.M., Sortwell, C.E., Steece‐Collier, K., Daley, B.F., Booms, A., Lipton, J.W., Welch, M., Berman, M., Jandreski, L., Graham, D.L., Weihofen, A., Celano, S.L., Schulz, E., Cole-Strauss, A., Luna, E., Quach, D., & Mohan, A. (2019). Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.1101/830554
Vancouver
Cole TA, Zhao HT, Collier TJ, Sandoval IM, Sortwell CE, Steece‐Collier K, et al. Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. bioRxiv (Cold Spring Harbor Laboratory). 2019. doi:10.1101/830554.
BibTeX
@unpublished{tracy2019Alphas,
title = {Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease},
author = {Tracy A. Cole and Hien Tran Zhao and Timothy J. Collier and Ivette M. Sandoval and Caryl E. Sortwell and Kathy Steece‐Collier and Brian F. Daley and Alix Booms and Jack W. Lipton and Mackenzie Welch and Melissa Berman and Luke Jandreski and Danielle L. Graham and Andreas Weihofen and Stephanie L. Celano and Emily Schulz and Allyson Cole-Strauss and Esteban Luna and Duc Quach and Apoorva Mohan and C. Frank Bennett and Eric E. Swayze and Holly B. Kordasiewicz and Kelvin C. Luk and Katrina L. Paumier},
journal = {bioRxiv (Cold Spring Harbor Laboratory)},
year = {2019},
doi = {10.1101/830554},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
JCI Insight 2021
Open access · CC-BY
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
2026
Citation only
Parkinson’s Disease
Scientific Reports 2018
Open access · CC-BY
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
PLoS Genetics 2008
Open access · CC-BY
C. elegans Model Identifies Genetic Modifiers of α-Synuclein Inclusion Formation During Aging
Frontiers in Aging Neuroscience 2020
Open access · CC-BY
Protein-Protein Interactions in Alpha-Synuclein Biogenesis: New Potential Targets in Parkinson’s Disease
Annals of Clinical and Translational Neurology 2016
Open access · CC-BY